Cytomegalovirus (CMV) Clinical Trial
Official title:
A Multinational, Non-Interventional, Retrospective Study on CMV Infection Outcomes, Treatment Patterns and Healthcare Utilization Study (OTUS) Among Solid Organ Transplant (SOT) Recipients in Europe and Canada (OTUS SOT Extension in the EUCAN Countries: Austria, Belgium, Canada, Greece, Israel, Italy, Netherlands, Poland and Sweden)
The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe [EU] and Canada [CAN]). Data will be collected retrospectively from medical charts. No study medicines will be provided to participants in this study.
This study consists of two cohorts: Cohort 1 (resistant, refractory or intolerant to anti-CMV agents) includes participants who had an SOT after January 1, 2016. Cohort 2 (pre-emptive treatment for CMV viremia) includes participants who had an SOT after January 1, 2019. Participants who meet the criteria for both cohorts will be evaluated in each cohort separately (i.e., Cohort 1 and Cohort 2 are not mutually exclusive, and participants will be analyzed in both cohorts using unique index dates with respect to the cohort-specific eligibility criteria). Participant follow-up in the medical record must be available for at least one year from the CMV index date or death, whichever occurs first. The start date of data collection corresponds to the end of participant follow up. For Cohort 1, it is expected that follow-up data will be available for up to 7 years (for those participants with an index date in 2016 and followed through 2022). For Cohort 2, it is expected that follow-up data will be available for up to 4 years (for those participants with an index date in 2019 and followed through 2022). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05319353 -
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection
|
Phase 3 | |
| Completed |
NCT05571137 -
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
|
||
| Not yet recruiting |
NCT06243731 -
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
|
||
| Not yet recruiting |
NCT06439342 -
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
|
Phase 3 | |
| Not yet recruiting |
NCT06213974 -
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
|
||
| Completed |
NCT02775240 -
Study of SHP620 (Maribavir) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01611974 -
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
|
Phase 2 | |
| Completed |
NCT05137717 -
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
|
Phase 3 | |
| Completed |
NCT02931539 -
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
|
Phase 3 | |
| Completed |
NCT02927067 -
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
|
Phase 3 |